{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:19:45Z","timestamp":1768339185988,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.medcli.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T14:53:37Z","timestamp":1524322417000},"page":"275-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Terapias avanzadas en enfermedades raras: la atrofia muscular espinal como ejemplo"],"prefix":"10.1016","volume":"151","author":[{"given":"Eduardo F.","family":"Tizzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2018.03.001_bib0105","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.03.001_bib0110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.03.001_bib0115","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.03.001_bib0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nmd.2008.10.004","article-title":"Ramblings in the history of spinal muscular atrophy","volume":"19","author":"Dubowitz","year":"2009","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.medcli.2018.03.001_bib0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"key":"10.1016\/j.medcli.2018.03.001_bib0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.medcli.2018.03.001_bib0135","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2017.02.014","article-title":"Revisiting the consensus on standards of care in SMA, Naarden, The Netherlands, 19-21 February 2016","volume":"27","author":"Finkel","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.medcli.2018.03.001_bib0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-017-0695-0","article-title":"Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain","volume":"12","author":"L\u00f3pez-Bastida","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.medcli.2018.03.001_bib0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","article-title":"Mutation update of spinal muscular atrophy in Spain: Molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene","volume":"125","author":"Al\u00edas","year":"2009","journal-title":"Hum Genet."},{"key":"10.1016\/j.medcli.2018.03.001_bib0150","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/cge.12222","article-title":"Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene","volume":"85","author":"Al\u00edas","year":"2014","journal-title":"Clin Genet."},{"key":"10.1016\/j.medcli.2018.03.001_bib0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.medcli.2018.03.001_bib0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh","year":"2017","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.medcli.2018.03.001_bib0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal Muscular Atrophy: Why do low levels of SMN make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat Rev Neurosci."},{"key":"10.1016\/j.medcli.2018.03.001_bib0170","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet."},{"issue":"Suppl. 1","key":"10.1016\/j.medcli.2018.03.001_bib0175","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.ejpn.2017.04.1218","article-title":"Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): Interim results from the NURTURE study","volume":"21","author":"Bertini","year":"2017","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1016\/j.medcli.2018.03.001_bib0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","article-title":"A qualitative study of perceptions of meaningful change in spinal muscular atrophy","volume":"17","author":"McGraw","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.medcli.2018.03.001_bib0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.medcli.2018.03.001_bib0190","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: A changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.medcli.2018.03.001_bib0195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/j.semperi.2015.03.006","article-title":"Newborn screening for spinal muscular atrophy: Anticipating an imminent need","volume":"39","author":"Phan","year":"2015","journal-title":"Semin Perinatol."},{"key":"10.1016\/j.medcli.2018.03.001_bib0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/gt.2017.32","article-title":"New treatments for serious conditions: ethical implications","volume":"24","author":"King","year":"2017","journal-title":"Gene Ther."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318301696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318301696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T18:34:16Z","timestamp":1537468456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775318301696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0025775318301696"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2018.03.001","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Terapias avanzadas en enfermedades raras: la atrofia muscular espinal como ejemplo","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}